Abstract. Ganoderma lucidum, an oriental medical mushroom, has been used in Asia for the prevention and treatment of a variety of diseases, including cancer. We have previously demonstrated that G. lucidum inhibits growth and induces cell cycle arrest at G 0 /G 1 phase through the inhibition of Akt/NF-κB signaling in estrogen-independent human breast cancer cells. However, the molecular mechanism(s) responsible for the inhibitory effects of G. lucidum on the proliferation of estrogen-dependent (MCF-7) and estrogenindependent (MDA-MB-231) breast cancer cells remain to be elucidated. Here, we show that G. lucidum inhibited the proliferation of breast cancer MCF-7 and MDA-MB-231 cells by the modulation of the estrogen receptor (ER) and NF-κB signaling. Thus, G. lucidum down-regulated the expression of ER· in MCF-7 cells but did not effect the expression of ERß in MCF-7 and MDA-MB-231 cells. In addition, G. lucidum inhibited estrogen-dependent as well as constitutive transactivation activity of ER through estrogen response element (ERE) in a reporter gene assay. G. lucidum decreased TNF-·-induced (MCF-7) as well as constitutive (MDA-MB-231) activity of NF-κB. The inhibition of ER and NF-κB pathways resulted in the down-regulation of expression of c-myc, finally suppressing proliferation of estrogen-dependent as well as estrogen-independent cancer cells. Collectively, these results suggest that G. lucidum inhibits proliferation of human breast cancer cells and contain biologically active compounds with specificity against estrogen receptor and NF-κB signaling, and implicate G. lucidum as a suitable herb for chemoprevention and chemotherapy of breast cancer.
Introduction
Estrogens exert their biological effects such is the induction of cell proliferation through the interaction with estrogen receptor-alpha (ER·) and ER-beta (ERß) (1) (2) (3) . The liganded ER forms homo-/hetero-dimers, translocate into nucleus and activate transcription of target genes through the binding to estrogen response elements (EREs) in their promoter region (2, (4) (5) (6) . The activation of ER· stimulates cell proliferation while ERß has an opposite effect (7) (8) (9) . Therefore, selective estrogen receptor modulators (SERMs) are widely used for the treatment of breast cancer in ER·-positive breast tumors (10, 11) . However, breast cancer often progresses from the estrogen-dependent, nonmetastatic phenotype (ER·-and ERß-positive) to the estrogen-independent, metastatic phenotypes (ER·-negative and ERß-positive) (11) .
Constitutively active transcription factor nuclear factor-κB (NF-κB) and increased expression of c-myc were found in breast cancer cells (12, 13) and linked to their high proliferative potential (3, 13, 14) . Since the expression of c-myc is regulated by 17ß-estradiol (E2) (15, 16) and NF-κB (17) , the levels of c-myc in estrogen-dependent and estrogen-independent breast cancer cells can be modulated through the inhibition of ER and NF-κB signaling pathways. We and others have demonstrated that the increased activity of NF-κB is associated with the invasive behavior and aggressive tumor growth of ER·-negative breast cancer cells, and found that the inhibition of NF-κB results in the suppression of invasiveness and growth of these cells (12, 18) .
The extracts from a medicinal mushroom Ganoderma lucidum (Reishi) have been widely used in Asian countries to treat various human diseases, including cancers. The anticancer properties of G. lucidum have been attributed to a variety bioactive compounds including polysaccharides and lanostanebased triterpenes (19, 20) . We have recently demonstrated that transcription factor NF-κB controls invasive behavior of highly metastatic breast cancer cells (18) , and that G. lucidum inhibits invasiveness of breast cancer cells through the suppression of NF-κB, resulting in the down-regulation of the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) (21) . We have also found that G. lucidum inhibits the growth of breast cancer cells through the cell cycle arrest at G 0 /G 1 , which was mediated by the suppression of Akt/NF-κB
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In the present study, we investigated the molecular mechanism(s) responsible for the inhibitory effects of G. lucidum on the proliferation of estrogen-dependent MCF-7 (ER·-, ERß-positive) and estrogen-independent MDA-MB-231 (ER·-negative, ERß-positive) human breast cancer cells. We demonstrated that G. lucidum down-regulates the expression of ER·, inhibits estrogen-inducible ER transactivation and inhibits TNF-·-stimulated activation of NF-κB in MCF-7 cells. G. lucidum also suppressed constitutive activity of ERE and NF-κB in MDA-MB-231 cells. The inhibition of inducibleas well as constitutive-estrogen receptor and NF-κB pathways resulted in the down-regulation of expression of c-myc, finally resulting in the suppression of proliferation of MCF-7 and MDA-MB-231 breast cancer cells.
Materials and methods
Materials. G. lucidum (Reishimax) was purchased from Pharmanex (Provo, UT). According to the manufacturer, this sample contains 13.5% polysaccharides and 6% triterpenes. Further analysis by LC-MS demonstrated the presence of ganoderic acids A, F and H, which can be used for the standardization of G. lucidum (Thyagarajan et al, unpublished data). G. lucidum was dissolved in sterile water at a concentration of 50 mg/ml and stored at 4˚C. 17ß-estradiol was purchased from Sigma (St. Louis, MO), tamoxifen was purchased from Calbiochem (La Jolla, CA).
Cell culture. The human breast cancer cell lines (MCF-7 and MDA-MB-231) were obtained from ATCC (Manassas, VA). MCF-7 and MDA-MB-231 cells were maintained in phenol red-free Dulbecco's modified Eagle's medium (DMEM) containing penicillin (50 U/ml), streptomycin (50 U/ml), and 10% fetal bovine serum (FBS). 293T/NF-κB-luc cell line was obtained from Panomics (Redwood City, CA). 293T/NF-κB-luc cells were maintained in DMEM containing penicillin (50 U/ml), streptomycin (50 U/ml), hygromycin (100 μg/ml) and 10% FBS. Media and supplements were from Invitrogen (Grand Island, NY). FBS and Charcoal/Dextran treated FBS (CDFBS) were obtained from Hyclone (Logan, UT). Dulbecco's phosphate-buffered saline (DPBS) was purchased from Cambrex Bio Science Walkersville, Inc. (Walkersville, MD).
Cell proliferation assay. Cell proliferation was determined by the tetrazolium salt method (MTT method), according to the manufacturer's instructions (Promega, Madison, WI). Briefly, MCF-7 and MDA-MB-231 cells (2.5x10 3 /well) were cultured in a 96-well plate and treated with G. lucidum (0-0.25 mg/ml) for 24 and 48 h. At the end of the incubation period, the cells were harvested and absorption was determined with an ELISA plate reader at 570 nm. Data points represent mean ± SD in one experiment repeated at least twice.
Real-time reverse transcription-PCR.
Real-time RT-PCR was used to determine the expression levels of ER· and ERß mRNA in human breast cancer cells. The total RNA from breast cancer cells was isolated by RNeasy Mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Reverse transcription was performed as previously described (23) . The PCR primers and TaqMan probes for ER·, ERß, and ß-actin were synthesized from MWG (High Point, NC). PCR was performed by mixing 5 μl of RT product with 2X QuantiTect Probe PCR master mix (Qiagen), and 0.375 μl of primer/probe mixture in a total of 25 μl. Real-time quantitative PCR analysis was performed using an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The amplifications were performed in duplicate for each sample and the PCR conditions were as follows: initial incubation at 50˚C for 2 min, denaturation at 95˚C for 10 min, followed by 40 cycles at 95˚C for 15 sec, and 60˚C for 1 min. We analyzed the relative quantitation of gene expression by the comparative C T (ΔΔC T ) method (24) . Briefly, the threshold cycle (C T ) was obtained as the fractional cycle number at which the amount of amplified target reached a fix threshold. Data normalization was performed by subtracting C T value of the ß-actin from that of the target gene. The ΔΔC T was calculated as the difference of the normalized C T value ΔC T ) of the treatment and control samples. ΔΔC T =ΔC T treatment -ΔC T control . The comparative expression level of target genes is equal to 2-ΔΔCT .
DNA transfection and luciferase assay. MCF-7, MDA-MB-231 and 293T/NF-κB-luc cells (2.5x10 5 /well) were seeded into 6-well plates in DMEM with 10% FBS prior to transfection. Transient transfections were performed with the Effectene reagent (Qiagen) according to the manufacturer's instructions. Briefly, the cells were transfected with ERE-II-luc (8) or NF-κB-luc (BD Biosciences Clontech, Palo Alto, CA) reporter constructs (1 μg) and ß-galactosidase expression vector pCH110 (1 μg) while 293T/NF-κB-luc cells were transfected with pSG5 or ER· (25) or ERß (26) expression vector constructs (1 μg) and ß-galactosidase expression vector pCH110 (1 μg). Twenty hours after transfection, cells were washed once with DPBS and the medium was replaced with DMEM with 2% CDFBS. Cells were treated with E2 (10 nM), tamoxifen (1 μM), and G. lucidum (0.5 mg/ml) for 20 h followed by the treatment with TNF-· (50 ng/ml) for an additional 4 h. ß-glactosidase activity was measured in cell lysates, as previously described (18) . Normalized amounts (equal numbers ß-galactosidase units) of cell extracts were used in luciferase assay using Lmax luminometer (Molecular Devices, Sunnyvale, CA). Data points represent the mean ± SD of three independent transfection experiments.
Preparation of nuclear and whole cell extract. MCF-7 and MDA-MB-231 cells (1x10 7 ) were treated with G. lucidum (0-1.0 mg/ml) for 24 h. Whole cell extracts were prepared as described (22) . Nuclear extracts were isolated from cells resuspended with 0.5 ml of ice-cold RSB lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 1 mM DTT, and protease inhibitor cocktail Complete™), by dounce homogenization. The nuclei were collected by centrifugation and the nuclear pellet was resuspended in 3 Vol of Buffer C (20% glycerol, 20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.2 mM PMSF, 1 mM DTT, 100 μM Na 3 VO 4 and protease inhibitor cocktail Complete™), incubated for 30 min, and the final supernatant (nuclear extract) collected by centrifugation. The protein concentration in whole cell and nuclear extract was determined according to the manufacturer's protocol (Bio-Rad Laboratories, Hercules, CA).
Electrophoretic mobility shift assay (EMSA).
Oligonucleotide probes containing consensus sequences for ERE and NF-κB binding sites were purchased from Santa Cruz Biotechnology and Promega (Madison, WI), respectively. EMSA for NF-κB was performed as previously described (18) . EMSA for ERE was carried out in binding buffer [5% glycerol, 20 mM HEPES pH 7.9, 100 mm KCl, 1 mM EDTA, 2.5 mM DTT, and 2.0 μg poly-dIdC] with 5 μg of nuclear protein on ice for 20 min. One μl (40,000 cpm) of [ 32 P]-labeled ERE probe was added to the reaction mixture and incubated for another 20 min at room temperature. The reaction mixture was then separated on a 4.5% PAGE gel in 0.25X Tris/borate/EDTA (TBE) buffer. The specificity was confirmed by competitive EMSA with cold ERE oligonucleotide or unrelated DNA (URL), and supershift analysis with anti-ER· or anti-ERß antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Western blot analysis. Equal amounts of proteins (20 μg/lane)
were separated on 4-12% SDS-PAGE and transferred to a PVDF membrane (Millipore, Bedford, MA). The membrane was incubated with the corresponding primary antibodies diluted 1:1000 in blocking solution, as follows: a mouse anti-ER· monoclonal antibody, a rabbit anti-ERß polyclonal antibody, a mouse anti-c-Myc monoclonal antibody, and a mouse anti-actin monoclonal antibody (Santa Cruz Biotechnology). Anti-mouse or anti-rabbit secondary antibodies (Amersham Biosciences, Buckinghamshire, UK) were used for detection and visualization by the ECL Western blotting detection system (Amersham Biosciences).
Densitometric analysis. Autoradiograms of the Western blots were scanned with hp scanjet 5470c scanner. The optical densities of ER·, ERß, c-myc and ß-actin proteins on the film were quantified and analyzed with the UN-SCAN-IT software (Silk Scientific, Orem, UT). The ratios of ER·/actin, ERß/actin, and c-myc/actin were calculated by standardizing the ratios of each control to the unit value.
Results

G. lucidum inhibits proliferation of non-invasive as well as invasive breast cancer cells.
We have recently demonstrated that an extract from medicinal mushroom G. lucidum inhibits proliferation of highly invasive human breast cancer cells (22) . In order to evaluate effects of G. lucidum on the growth of non-invasive, estrogen-dependent (MCF-7), and highlyinvasive, estrogen-independent (MDA-MB-231) breast cancer cells, the cells were treated with G. lucidum (0-0.25 mg/ml) for 24 and 48 h. As seen in Fig. 1A , G. lucidum inhibits the growth of MDA-MB-231 cells in a dose-and-time dependent manner. However, G. lucidum demonstrates more profound effect on MCF-7 cells since the concentration of 31 μg/ml inhibited proliferation of MCF-7 cells by 47-61% within 24-48 h, whereas the same dose inhibited proliferation of MDA-MB-231 cells only by 23-20%, respectively (Fig. 1B) . The inhibition of proliferation is not caused by the cytotoxicity of G. lucidum because, as we previously demonstrated, the viability of breast cancer cells is not affected by the concentration up to 1.0 mg/ml (22) . These results suggest that estrogen-dependent (MCF-7) cells are more sensitive to G. lucidum than estrogen-independent (MDA-MB-231) cells.
Effect of G. lucidum on the expression of ER alpha and ER beta in breast cancer cells.
To confirm the status of estrogen receptors in breast cancer cells, the whole cell lysates were prepared from MCF-7 and MDA-MB-231 cells and subjected to Western blot analysis with anti-ER· and anti-ERß antibody, respectively. As expected, MCF-7 estrogen-dependent breast cancer cells express ER· and ERß, whereas estrogenindependent MDA-MB-231 cells express only ERß (Fig. 2A) . In order to determine whether the inhibition of cell growth is related to the status of estrogen receptors, we examined the shown). In contrast, G. lucidum markedly decreased the levels of ER· protein in MCF-7 cells in a dose-dependent manner (Fig. 2B) , whereas the same treatment did not affect the expression of ERß (Fig. 2C) . In addition, the expression of and ERß was also not affected by G. lucidum in MDA-MB-231 cells (Fig. 2D) . To clarify the mechanism of regulation of ER· expression in breast cancer cells, MCF-7 cells were treated with G. lucidum (0.5 mg/ml), inhibitor of transcription Actinomycin D (Act D, 1 μg/ml), and inhibitor of translation cycloheximide (CHX, 10 μg/ml). As seen in Fig. 2E , G. lucidum as well as CHX or the combination of both markedly inhibited the expression of ER·, whereas Act D or the combination of ActD with G. lucidum did not markedly change the expression of ER· in MCF-7 cells. These results suggest that different mechanisms regulate expression of ER· and ERß, and that G. lucidum regulates expression of ER· at the translational level.
G. lucidum inhibits estrogen receptor mediated transcription activity in breast cancer cells.
Natural estrogenic compounds mediate their transcriptional activity through the interaction with ER· and ERß (27) . As we show above, G. lucidum inhibits proliferation of breast cancer cells expressing both ER·/ERß or only ERß. In order to determine whether the effects of G. lucidum are mediated through the inhibition of the transcriptional activation of estrogen receptor signaling, MCF-7 and MDA-MB-231 cells were transfected with reporter gene constructs ERE-luc, and treated with E2 (10 nM), TAM (1 μM), and G. lucidum (0.5 mg/ml) for 24 h, respectively. As seen in Fig. 3A , G. lucidum suppressed constitutive (control vs GL) as well as estrogen-induced (E2 vs E2 + GL) transcriptional activation in MCF-7 cells. Although G. lucidum and TAM inhibited the constitutive ERE activity in a similar manner, this effect was not additive or synergistic. Furthermore, G. lucidum inhibited also constitutive ERE activity (control vs GL) in MDA-MB-231 cells (Fig. 3B) . As expected E2 does not stimulate ERE activity in MDA-MB-231 cells and also the effect of TAM was not so dramatic in these cells (Fig. 3B) . To evaluate if the suppression of transcriptional activation through ERE is the result of the inhibition of the DNA-binding, we have performed gel shift analysis with nuclear extracts from MCF-7 and MDA-MB-231 cells with [ 32 ]P-labeled ERE DNA-binding oligonucleotide probe. As seen in Fig. 3C , nuclear extracts from MCF-7 cells bind specifically to the ERE, and G. lucidum inhibited ERE-binding. In addition, G. lucidum also inhibited ERE-binding in MDA-MB-231 cells (not shown). In summary, G. lucidum inhibits ERE transactivation activity mediated through ER· and ERß in breast cancer cells.
G. lucidum inhibits constitutive as well as inducible NF-κB activity through estrogen receptor-independent as well as estrogen receptor-dependent pathways.
The constitutive activation of NF-κB contributes to the progression of breast cancer to estrogen-independent growth and more aggressive phenotype of breast cancer cells (28, 29) . We have previously demonstrated that G. lucidum decreased constitutively active NF-κB resulting in the cell cycle arrest at G 0 /G 1 and inhibition of proliferation of MDA-MB-231 cells (21, 22) . In order to evaluate the effect of G. lucidum on inducible NF-κB activation, MCF-7 cells were transfected with reporter gene constructs NF-κB-luc, and treated with TNF-·, E2, TAM and G. lucidum as described in Materials and methods. As expected, TNF-· stimulated NF-κB activity in MCF-7 cells, and this activity was inhibited by G. lucidum (Fig. 4A , control + TNF-· vs TNF-· + GL). In addition, E2 treatment further increased TNF-· stimulated NF-κB activity, which was also inhibited by the treatment with G. lucidum (Fig. 4A , TNF-· + E2 vs TNF-· + E2 + GL), and tamoxifen further enhanced the inhibitory effect of G. lucidum (Fig. 4A , TNF-· vs TNF-· + TAM + GL). In order to confirm that G. lucidum inhibits DNA-binding of NF-κB in TNF-·-stimulated MCF-7 cells, nuclear extracts were prepared and subjected to gel shift . Twenty-four hours after transfection, the cells were treated with E2 (10 nM), tamoxifen (TAM, 1 μM), G. lucidum (GL, 0.5 mg/ml) or the combination of E2 with GL or TAM with GL for 20 h, followed by a 4-h incubation with TNF-· (50 ng/ml). NF-κB activity was measured as described in Materials and methods. The results are expressed as the percentage of relative NF-κB activity. Each bar represents the mean ± SD of three experiments.
analysis with [ 32 P]-labeled NF-κB oligonucleotide probe. As seen in Fig. 4B , G. lucidum inhibits DNA-binding of inducible NF-κB; the specificity of this inhibition was confirmed by competition and supershift assays (18) . As we have previously reported, G. lucidum inhibits constitutively active NF-κB in MDA-MB-231 cells (21, 22) . However, this effect can be enhanced by the combination of G. lucidum with tamoxifen (Fig. 4C , control vs GL vs TAM + GL).
In order to elucidate the role of estrogen receptors in the inhibition of NF-κB mediated by G. lucidum, we employed HEK-293 containing NF-κB-luciferase reporter gene (293T/NF-κB-luc). These cells do not express endogenous ER· or ERß, and G. lucidum markedly inhibited TNF-·-induced NF-κB activity (Fig. 5A) . Interestingly, E2 further stimulated TNF-·-induced NF-κB activity in 293T/NF-κB-luc cells transfected with ER·, and this NF-κB activity was also suppressed by G. lucidum (Fig. 5B) . Moreover, TNF-·-induced NF-κB activity in 293T/NF-κB-luc cells transfected with ERß was also decreased by G. lucidum (Fig. 5C) .
In summary, G. lucidum inhibits constitutive as well as inducible activation of NF-κB, and this inhibition can be mediated through ER· or ERß, or can be estrogen receptor independent.
G. lucidum down-regulates expression of c-myc in breast cancer cells.
Increased expression of the oncogene c-myc has been detected in a majority of breast cancers (13) . Because the expression of c-myc is controlled by estrogen and by NF-κB (15-17), we hypothesized that G. lucidum also modulates expression of c-myc in breast cancer cells. Although estradiol markedly induced expression of c-myc in MCF-7 cells, G. lucidum down-regulated expression of c-myc in a dose response manner (Fig. 6A) . As expected, E2 did not stimulate c-myc expression in estrogen-independent MDA-MB-231 cells, and the constitutive c-myc expression was also down-regulated by G. lucidum in a dose-response manner (Fig. 6B) . These results suggest that the inhibitory effects of G. lucidum on the growth of MCF-7 and MDA-MB-231 cells can be associated with the down-regulation of estrogendependent as well as estrogen-independent expression of c-myc.
Discussion
We have previously demonstrated that G. lucidum inhibits invasive behavior and proliferation of highly metastatic estrogen-independent breast cancer cells through the suppression of constitutively active NF-κB (21, 22, 30) . Nevertheless, the effect of G. lucidum on the most pertinent signaling network involved in breast cancer -estrogen receptor signaling, remains to be elucidated. In the present study, we evaluated the effect of G. lucidum on the estrogen-dependent, poorly invasive breast cancer cells (MCF-7) and estrogen-independent, highly invasive breast cancer cells (MDA-MB-231). We showed that G. lucidum can mediate, in part, its antiproliferative effect through the inhibition of ER and NF-κB signaling, resulting in the down-regulation of expression of c-myc in breast cancer cells (Fig. 7) .
Estrogen receptor signaling is a complex process, which can be controlled at the level of expression of estrogen receptor or at the level of its function as a transcription factor regulating expression of estrogen-responsive genes. Here we show that G. lucidum down-regulated the expression of ER· in MCF-7 cells. This effect was specific for ER· because the expression of ERß in MCF-7 or MDA-MB-231 cells was not affected by the G. lucidum treatment. Since estrogen activities responsible for cell proliferation of breast cancer (22) . Finally, the down-regulation of expression of ER· by ethanol extract of G. lucidum was also demonstrated in prostate cancer cells (32) .
At the transcription level, G. lucidum suppressed estrogen signaling by the inhibition of transactivation of estrogen receptor using reporter gene construct linked to the estrogen response element (ERE). Therefore, G. lucidum inhibits constitutive as well as E2-induced ERE transactivation in estrogen-dependent MCF-7 cells, and constitutive ERE transactivation in estrogen-independent MDA-MB-231 cells. The suppression of transcriptional activity through ER· and ERß by G. lucidum, suggests that G. lucidum triterpenes could exert selective estrogen receptor modulator (SERM) activities. However, due to the complex composition of G. lucidum extract, containing polysaccharides and triterpenes, we were not able to detect specific binding to ER (not shown). Interestingly, structurally related triterpenes isolated from the plant Ferula modulated estrogenic activity also through the interaction with ER· and ERß (33) . In addition, markedly lower doses of G. lucidum inhibited proliferation of MCF-7 (ER·-positive, ERß-positive) than of MDA-MB-231 (ER·-negative, ERß-positive) cells. This effect was mimicked by the typical SERM anti-estrogen tamoxifen, which inhibits ER·-negative breast cancer cells only at higher concentrations (34) . Furthermore, inhibition of proliferation of breast cancer cells by G. lucidum is mediated by the cell cycle arrest at G 0 /G 1 (22) , which is a typical mechanism for anti-estrogens regulation of cell cycle (35) .
We have previously demonstrated that G. lucidum inhibits constitutively active NF-κB in MDA-MB-231 cells (21) . In the present study we show that G. lucidum also inhibits inducible activation of NF-κB independently of status of estrogen receptor in cells. Thus, G. lucidum inhibited NF-κB in cells which do not express ER (HEK-293), in cells expressing ER· (HEK-293 overexpressing ER·), in cells expressing ERß (MDA-MB-231 and HEK-293 overexpressing ERß) or in cells expressing ER· and ERß (MCF-7). However, estradiol and TNF-·-stimulated NF-κB activity was inhibited by G. lucidum only in cells expressing ER·, suggesting that G. lucidum modulates cross-talk between ER and NF-κB. Although the original model of the interaction between NF-κB and ER· suggested inhibition of NF-κB by E2 (36), here we demonstrate that E2 in fact, under certain conditions, may also induce NF-κB. Furthermore, the positive regulation of NF-κB-and ER·-responsive genes c-myc and cyclin D1, via the promoter association of IκB kinase (IKK· and ER·), resulted in the enhanced proliferation of breast cancer cells (37) .
We demonstrate that G. lucidum down-regulated the E2-dependent as well as constitutive expression of c-myc in breast cancer cells. The inhibition of E2-stimulated c-myc expression in ER·-positive cells is consistent with our data demonstrating inhibition of E2-dependent trans-activation activity in MCF-7 cells by G. lucidum. Given that tamoxifen inhibits proliferation and c-myc expression in ER·-positive breast cancer cells (38) (39) (40) our data further suggest an antiestrogenic effect of G. lucidum. However, the downregulation of c-myc, which is constitutively active and is not activated by E2 in ER·-negative breast cancer cells, demonstrates the inhibitory effect of G. lucidum also on NF-κB pathway.
In conclusion, we present a possible mechanism by which G. lucidum inhibits proliferation of estrogen-dependent as well as estrogen-independent human breast cancer cells. The biological effects of G. lucidum on estrogen-dependent MCF-7 cells are mediated through the down-regulation of ER· expression, inhibition of estrogen-inducible ER transactivation and inhibition of TNF-·-stimulated activation of NF-κB. The effects on estrogen-independent MDA-MB-231 cells are mediated through the suppression of constitutive activity of ERE and NF-κB. The inhibition of inducible-as well as constitutive ER and NF-κB pathways results in the down-regulation of expression of c-myc, finally resulting in the suppression of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells. Further studies are in progress to identify biologically active compounds in G. lucidum with specificity against estrogen receptor and NF-κB signaling. 
